Aquestive Therapeutics, Inc. Q2 2025 Earnings Recap

Aquestive Therapeutics reported steady progress toward the anticipated FDA approval of Anaphylm, an innovative sublingual film for treating severe allergic reactions, with substantial market potential amidst ongoing pre-commercial activities.

Key Takeaways

• Anaphylm is on track for a scheduled FDA action date of January 31, 2026, with no significant safety issues reported in the recent update.
• The market for severe allergic reaction treatments is projected to expand from 5 million to 10 million prescriptions annually, potentially creating a $2 billion revenue opportunity.
• Aquestive plans to launch a patient-first cash pay program to ensure immediate access to Anaphylm, addressing barriers to insurance coverage and enhancing patient accessibility.
• The company has successfully completed its first in-house Advisory Committee meeting and is actively preparing for potential further discussions with key opinion leaders.
• Ongoing international expansion efforts for Anaphylm are being pursued alongside pre-commercial activities, positioning the company strategically for market entry.